Have Insiders Been Selling BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares This Year?

We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So before you buy or sell BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), you may well want to know whether insiders have been buying or selling.

What Is Insider Selling?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock on the market. However, rules govern insider transactions, and certain disclosures are required.

We don’t think shareholders should simply follow insider transactions. But logic dictates you should pay some attention to whether insiders are buying or selling shares. For example, a Columbia University study found that ‘insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers’.

See our latest analysis for BioMarin Pharmaceutical

Want to help shape the future of investing tools and platforms? Take the survey and be part of one of the most advanced studies of stock market investors to date.

The Last 12 Months Of Insider Transactions At BioMarin Pharmaceutical

Over the last year, we can see that the biggest insider sale was by President of Worldwide Research & Development Henry Fuchs for US$2.5m worth of shares, at about US$100.00 per share. That means that an insider was selling shares at around the current price of US$93.15. They might be selling for a variety of reasons, but it’s hard to argue this is a bullish sign. We generally tread carefully if insiders have been selling on market, even if they sold slightly above the current price.

We note that in the last year insiders divested 44.42k shares for a total of US$4.4m. In total, BioMarin Pharmaceutical insiders sold more than they bought over the last year. The sellers received a price of around US$99.51, on average. It’s not ideal to see that insiders have sold at around the current price. Since insiders sell for many reasons, we wouldn’t put too much weight on it. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

NasdaqGS:BMRN Insider Trading January 16th 19
NasdaqGS:BMRN Insider Trading January 16th 19

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Does BioMarin Pharmaceutical Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. It appears that BioMarin Pharmaceutical insiders own 0.6% of the company, worth about US$87m. We’ve certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At BioMarin Pharmaceutical Tell Us?

The fact that there have been no BioMarin Pharmaceutical insider transactions recently certainly doesn’t bother us. Our analysis of BioMarin Pharmaceutical insider transactions leaves us cautious. But we do like the fact that insiders own a fair chunk of the company. Of course, the future is what matters most. So if you are interested in BioMarin Pharmaceutical, you should check out this free report on analyst forecasts for the company.

But note: BioMarin Pharmaceutical may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.